Last reviewed · How we verify

GSK 573719 +GW642444 125/25

GlaxoSmithKline · Phase 3 active Small molecule

GSK 573719 +GW642444 125/25 is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: High Dose Dual.

This combination inhaler delivers a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta-2 agonist (vilanterol) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

This combination inhaler delivers a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta-2 agonist (vilanterol) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameGSK 573719 +GW642444 125/25
Also known asHigh Dose Dual
SponsorGlaxoSmithKline
Drug classLong-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)
TargetMuscarinic M3 receptor; Beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

GSK 573719 (umeclidinium) is a long-acting anticholinergic that blocks muscarinic receptors on airway smooth muscle, preventing bronchoconstriction. GW642444 (vilanterol) is a long-acting beta-2 agonist that stimulates beta-2 receptors to promote bronchodilation. Together, these agents provide dual bronchodilation through complementary mechanisms, improving lung function and reducing symptoms in COPD patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK 573719 +GW642444 125/25

What is GSK 573719 +GW642444 125/25?

GSK 573719 +GW642444 125/25 is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drug developed by GlaxoSmithKline, indicated for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does GSK 573719 +GW642444 125/25 work?

This combination inhaler delivers a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta-2 agonist (vilanterol) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

What is GSK 573719 +GW642444 125/25 used for?

GSK 573719 +GW642444 125/25 is indicated for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes GSK 573719 +GW642444 125/25?

GSK 573719 +GW642444 125/25 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is GSK 573719 +GW642444 125/25 also known as anything else?

GSK 573719 +GW642444 125/25 is also known as High Dose Dual.

What drug class is GSK 573719 +GW642444 125/25 in?

GSK 573719 +GW642444 125/25 belongs to the Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class. See all Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drugs at /class/long-acting-muscarinic-antagonist-long-acting-beta-2-agonist-combination-lama-laba.

What development phase is GSK 573719 +GW642444 125/25 in?

GSK 573719 +GW642444 125/25 is in Phase 3.

What are the side effects of GSK 573719 +GW642444 125/25?

Common side effects of GSK 573719 +GW642444 125/25 include Tremor, Headache, Palpitations, Muscle cramps, Nasopharyngitis.

What does GSK 573719 +GW642444 125/25 target?

GSK 573719 +GW642444 125/25 targets Muscarinic M3 receptor; Beta-2 adrenergic receptor and is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA).

Related